Academic Editors: Andrea Tinelli and Michael H. Dahan
Background: Cesarean Scar Pregnancy (CSP) is a cause of severe maternal
morbidity. Currently, no guideline for its management is shared. We assessed
safety and effectiveness of Methotrexate (MTX) administration within the
sub-chorionic space under hysteroscopic guidance, followed by resectoscopic
placental removal. Methods: Five patients suffering from type 2 CSP
underwent a sequential treatment based on hysteroscopic techniques. Pregnancy
termination was firstly obtained by injection of 80 mg of MTX within the
intervillous spaces of placental site. The intervention was performed in an
office setting using a 16Fr hysteroscope. MTX was administered by a 17-gauge
needle suitable for the operative channel of hysteroscope. Subsequently, based on
the decline of Human Chorionic Gonadotropin
Abnormal placental implantation can develop within the scar of cervico-isthmic uterine junction following a previous cesarean delivery. Cesarean Scar Pregnancy (CSP) is considered an ectopic pregnancy and it has been estimated that 1 out of 500 women carrying a cesarean scar can develop a CSP [1]. If untreated, CSP exposes the patient to life-threatening complications such as uterine rupture during the first months of pregnancy (type 2 CSP, showing placental growth toward the bladder and abdominal cavity) or the development of a placenta previa-accreta (type 1 CSP, showing placental growth from cervico-isthmic space to endometrial cavity) [2, 3]. Early diagnosis and pregnancy termination represent the cornerstone of CSP management, aimed at sparing fertility and reducing maternal morbidity [4]. Established ultrasonographic criteria for an early diagnosis are available [2, 5] but no consensus on the most cost-effective management of CSP is currently shared. More than 30 treatment regimens, based on medical therapy, high intensity ultrasound, intrauterine double balloon insertion, surgical removal, uterine artery embolization (UAE) alone or combined, have been proposed in the management of CSP [1, 2, 6, 7]. The reversible inhibitor of dihydrofolate reductase (DHFR), Methotrexate (MTX), is widely used as medical therapy for CSP termination, either by systemic or local administration [2, 4, 8]. Nevertheless, when used alone MTX shows significant morbidity and slow pregnancy absorption, frequently needing additional interventions [1, 2, 8, 9]. Combined treatments, based on surgical removal of CSP following MTX administration or UAE showed an improvement of clinical outcomes [10, 11]. More than 10 years ago, Wang et al. [12] firstly described a safe hysteroscopic management of CSP. Subsequently, the effectiveness of hysteroscopy to treat CSP was suggested both as primary therapy and following MTX administration or UAE [10, 11, 13, 14]. Herein we propose a double-step technique based on hysteroscopically-driven subchorionic MTX administration followed by placental resectoscopic removal [15] and present the clinical outcome of a consecutive series of 5 patients suffering from type 2 CSP.
From January 2017 to January 2022 a consecutive series of 5 patients showing
type 2 CSP were diagnosed in the first trimester of pregnancy at the Obstetrics
and Gynecology Department of the Hospital of Lodi (Italy). All women underwent
one or more previous cesarean deliveries. The diagnosis of type 2 CSP was based
on the following established transvaginal ultrasound criteria: (i) An empty
endometrial cavity and an empty cervical canal. (ii) The gestational sac,
containing an embryonic pole viable or not, was found deeply embedded within the
uterine wall at the cervico-histhmic junction, bulging ventrally toward the
bladder. (iii) A trans-vaginal eco Color-Doppler showing a high blood-flow with
low impedance around the cervico-histhmic area [5]. Assuming that pregnancy
termination was wished, we proposed local MTX administration to the patients,
through office hysteroscopic guidance, followed by the resectoscopic removal of
pregnancy. All patients signed a tailored consent and an informative chart
displaying the potential hemorrhagic risks associated with the procedure.
Pre-treatment serum level of
The tip of the 17-gauge needle inserted in the operative channel of a 5-mm operative hysteroscope is shown within the coelomic space of a type 2 Cesarean Scar Pregnancy, before Methotrexate sub-chorionic administration.
Needle removal from sub-chorionic inter-villous placental space after Methotrexate administration.
Resectoscopic removal of CSP after hysteroscopic sub-chorionic administration of Methotrexate. The cleavage plane between the cervico-isthmic uterine niche (pinkish tissue) and villous trophoblast (blanching tissue) is developed by blunt loop separation.
Clinical features of the 5 patients are summarized in Table 1. An early
diagnosis of CSP, lasting from 6 to 8 weeks (mean gestational age 7.2 weeks), was
carried-out in all women. Vaginal bleeding led to emergency obstetrics
consultations in 3 patients whereas in 2 cases the diagnosis was suggested during
the first obstetric office visit in asymptomatic women. A viable pregnancy at
ultrasound was observed in 3 out of 5 patients. Hysteroscopy sub-chorionic
administration of MTX was easily accomplished in all patients without any
perioperative complication. The operating times were from 5 to 12 minutes (mean
operating time of 8.4 minutes), the VAS score ranged from 1 cm to 3 cm (mean VAS
score of 2.2 cm) and all patients were discharged after an uneventful 3–4 hours
period of observation. During the weekly observational time, all patients
recorded mild vaginal bleeding and in viable pregnancies the embryonic hearth
activity disappeared within 7 days since MTX administration. In all cases, the
sonography assessment found both the persistence of gestational sac and a
progressive decrease in placental blood flow. As depicted in Fig. 4, a
substantial drop of
Patients | Age | Obstetric history | Gestational age | Pregnancy viability | Symptoms | Basal |
1 | 28 | 2 CS | 7 weeks | yes | none | 55222 |
2 | 34 | 1 CS, 1 dilatation & curettage | 8 weeks | yes | AUB | 96000 |
3 | 42 | 2 CS | 8 weeks | no | none | 27000 |
4 | 36 | 1 CS, 1 Vaginal delivery | 7 weeks | yes | AUB | 18000 |
5 | 36 | 2 CS | 6 weeks | no | AUB | 12424 |
CS, Cesarean Section; AUB, Abnormal Uterine Bleeding. |
The basal and weekly serum
An early diagnosis and an active management of CSP are recommended to preserve
fertility and to prevent complications such as hemorrhage and uterine rupture [1, 16]. Although no consensus is currently shared, single-step surgery such as
vaginal, laparoscopic or laparotomic CSP excision and combined treatments such as
MTX administration or UAE followed by Dilatation and Curettage or hysteroscopy
placental removal are suggested as the most effective treatment regimens [1, 16, 17]. MTX represents the drug most extensively adopted for conservative CSP
treatment, either as single therapy or within therapeutic combined pathways [1, 8, 9, 16, 17]. The antiblastic MTX toxicity is based on a reversible inhibition
of DHFR, an enzyme playing a pivotal role in folate homeostasis that promotes the
conversion of dihydrofolate to tetrahydrofolates. These latter are required to
synthesize purine and pyrimidine rings, the precursors of DNA and RNA molecules.
The reversibility of MTX binding to DHFR with respect to the natural
dihydrofolates substrates, leads either drug concentration and time of cell
exposure two relevant determinants of cytotoxicity [18]. The short half-life of
MTX and the limited blood supply to scarred tissue around the CSP may justify the
low effectiveness of systemic MTX administration [2, 4, 11, 16, 17]. Driving MTX
administration directly within placental villous tissue may lead to greater
concentration able to enhance the level of DHFR inhibition, potentially improving
its therapeutic effectiveness. Ultrasound-guided MTX administration within the
gestational sac of CSP has improved the clinical results with respect to systemic
MTX, although in 26% to 39% of patient placental absorption takes a long time
with frequent failures requiring further treatments [2, 8, 9, 17]. The villous
trophoblast of the ectopic implantation, leading to the placental differentiation
within the scar niche, is the target tissue of MTX. The inhibition of placental
growth represents the mainstay measure to reduce the risks of uterine wall
rupture and hemorrhage. Miniaturized hysteroscopes enable an easy access within
the gestational sac allowing a quite simple identification of the placental site
implant [19]. Based on these assumptions we believed that the selective MTX
administration under hysteroscopy vision in sub-chorionic space of placental
implantation, may improve its cytotoxicity, enhancing the drug concentration
within the intervillous spaces. In the consecutive series of patients presented
here, the hysteroscopic approach enabled in all cases a clear CSP anatomy
assessment, allowing MTX administration in the subchorionic villous spaces of the
placental implantation within the uterine scar. With respect to hysteroscopy
guidance, ultrasound techniques of intra-gestational sac MTX administration may
be less selective in addressing drug administration, due to the possible
difficulty in positioning the needle tip within the tissue target [2, 9]. In
experienced hands, hysteroscopy MTX administration can be accomplished as
outpatient procedure and resulted as technically easy, quick, painless and safe.
Its effectiveness in pregnancy termination was demonstrated by the early embryos
demise, by the early increase of
We presented a case series of patients suffering from CSP and treated with a technique based on two sequential hysteroscopic steps. The first, aimed to terminate pregnancy, consisted of a selective MTX administration within the placental inter-villous spaces under hysteroscopic guidance. After appropriate timing, based on the evidence of trophoblastic demise, it was followed by a successful and uneventful resectoscopic placental removal. In well-established hysteroscopy context, this sequential minimally invasive approach can be considered an option for the treatment of CSP.
GG designed the research study and wrote the manuscript. MS, BN and EB performed the research. VB and MC provided help and advice on the experiments. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.
Given the characteristic of the report, institutional review board approval was not required. All subjects gave their informed consent for inclusion before they participated in the study.
We thank Mrs Caroline Calnan for the language revision of the Manuscript.
This research received no external funding.
The authors declare no conflict of interest. GG is serving as one of the Editorial Board members of this journal. We declare that GG had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to AT and MHD.